Literature DB >> 24047238

Antagonist molecules in the treatment of angina.

Ashish K Gupta1, David Winchester, Carl J Pepine.   

Abstract

INTRODUCTION: Management of chronic angina has evolved dramatically in the last few decades with several options for pharmacotherapy outlined in various evidence-based guidelines. AREAS COVERED: There is a growing list of drugs that are currently being investigated for treatment of chronic angina. These also include several herbal medications, which are now being scientifically evaluated as potential alternative or even adjunctive therapy for angina. Gene- and cell-based therapies have opened yet another avenue for management of chronic refractory angina in 'no-option' patients who are not candidates for either percutaneous or surgical revascularization and are on optimal medical therapy. An extensive review of literature using PUBMED, Cochrane database, clinical trial databases of the USA and European Union was done and summarized in this review. This review will attempt to discuss the traditional as well as novel therapeutic agents for angina. EXPERT OPINION: Several pharmacological and non-pharmacological therapeutic options are now available for treatment and management of chronic refractory angina. Renewed interest in traditional therapies and cell- and gene-based modalities with targeted drug delivery systems will open the doors for personalized therapy for patients with chronic refractory angina.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24047238      PMCID: PMC5540377          DOI: 10.1517/14656566.2013.834329

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  141 in total

1.  Serum cholesterol level, cigarette smoking, and vasomotor responses to L-arginine in narrowed epicardial coronary arteries.

Authors:  C Tentolouris; D Tousoulis; G J Davies; C Stefanadis; P Toutouzas
Journal:  Am J Cardiol       Date:  2000-02-15       Impact factor: 2.778

2.  Trial to show the impact of nicorandil in angina (IONA): design, methodology, and management.

Authors: 
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

3.  Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris.

Authors:  L Ceremuzyński; T Chamiec; K Herbaczyńska-Cedro
Journal:  Am J Cardiol       Date:  1997-08-01       Impact factor: 2.778

4.  Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation [WISE] Study Angiographic Core Laboratory).

Authors:  B L Sharaf; C J Pepine; R A Kerensky; S E Reis; N Reichek; W J Rogers; G Sopko; S F Kelsey; R Holubkov; M Olson; N J Miele; D O Williams; C N Merz
Journal:  Am J Cardiol       Date:  2001-04-15       Impact factor: 2.778

5.  Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease.

Authors:  Giuseppe Marazzi; Mauricio Wajngarten; Cristiana Vitale; Roberto Patrizi; Francesco Pelliccia; Otavio Gebara; Humberto Pierri; Josè Antonio F Ramires; Maurizio Volterrani; Massimo Fini; Giuseppe M C Rosano
Journal:  Int J Cardiol       Date:  2006-11-28       Impact factor: 4.164

6.  Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris.

Authors:  W H Frishman; S Glasser; P Stone; P C Deedwania; M Johnson; T D Fakouhi
Journal:  Am J Cardiol       Date:  1999-02-15       Impact factor: 2.778

7.  Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina.

Authors:  Cor Van Hove; Fabienne Carreer-Bruhwyler; Joseph Géczy; Arnold G Herman
Journal:  Atherosclerosis       Date:  2005-01-26       Impact factor: 5.162

8.  Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial).

Authors:  Hung-Fat Tse; Sukumaran Thambar; Yok-Lam Kwong; Philip Rowlings; Greg Bellamy; Jane McCrohon; Paul Thomas; Bruce Bastian; John K F Chan; Gladys Lo; Chi-Lai Ho; Wing-Sze Chan; Raymond Y Kwong; Anthony Parker; Thomas H Hauser; Jenny Chan; Daniel Y T Fong; Chu-Pak Lau
Journal:  Eur Heart J       Date:  2007-11-05       Impact factor: 29.983

9.  Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocin-induced diabetes.

Authors:  G M Reaven; H Chang; B B Hoffman
Journal:  Diabetes       Date:  1988-01       Impact factor: 9.461

10.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.

Authors:  Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

View more
  5 in total

Review 1.  Experimental and early investigational drugs for angina pectoris.

Authors:  Islam Y Elgendy; David E Winchester; Carl J Pepine
Journal:  Expert Opin Investig Drugs       Date:  2016-11-14       Impact factor: 6.206

Review 2.  Drug Therapy for Stable Angina Pectoris.

Authors:  Talla A Rousan; Sunil T Mathew; Udho Thadani
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 3.  Expert consensus document: A 'diamond' approach to personalized treatment of angina.

Authors:  Roberto Ferrari; Paolo G Camici; Filippo Crea; Nicolas Danchin; Kim Fox; Aldo P Maggioni; Athanasios J Manolis; Mario Marzilli; Giuseppe M C Rosano; José L Lopez-Sendon
Journal:  Nat Rev Cardiol       Date:  2017-09-07       Impact factor: 32.419

4.  Revascularization and outcomes in Veterans with moderate to severe ischemia on myocardial perfusion imaging.

Authors:  David E Winchester; Alexander J Bolanos; Anita Wokhlu; Rebecca J Beyth; Leslee J Shaw
Journal:  Mil Med Res       Date:  2017-04-01

5.  Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.

Authors:  Dongqing Huang; Shrabanti Chowdhury; Hong Wang; Sara R Savage; Richard G Ivey; Jacob J Kennedy; Jeffrey R Whiteaker; Chenwei Lin; Xiaonan Hou; Ann L Oberg; Melissa C Larson; Najmeh Eskandari; Davide A Delisi; Saverio Gentile; Catherine J Huntoon; Uliana J Voytovich; Zahra J Shire; Qing Yu; Steven P Gygi; Andrew N Hoofnagle; Zachary T Herbert; Travis D Lorentzen; Anna Calinawan; Larry M Karnitz; S John Weroha; Scott H Kaufmann; Bing Zhang; Pei Wang; Michael J Birrer; Amanda G Paulovich
Journal:  Cell Rep Med       Date:  2021-12-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.